Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells

Neuronal inclusions of hyperphosphorylated and aggregated tau protein are a pathological hallmark of several neurodegenerative tauopathies, including Alzheimer's disease (AD). The hypothesis of tau transmission in AD has emerged from histopathological studies of the spatial and temporal progression of tau pathology in postmortem patient brains. Increasing evidence in cellular and animal models supports the phenomenon of intercellular spreading of tau. However, the molecular and cellular mechanisms of pathogenic tau transmission remain unknown. The studies described herein investigate tau pathology propagation using human neurons derived from induced pluripotent stem cells. Neurons were seeded with full-length human tau monomers and oligomers and chronic effects on neuronal viability and function were examined over time. Tau oligomer-treated neurons exhibited an increase in aggregated and phosphorylated pathological tau. These effects were associated with neurite retraction, loss of synapses, aberrant calcium homeostasis, and imbalanced neurotransmitter release. In contrast, tau monomer treatment did not produce any measureable changes. This work supports the hypothesis that tau oligomers are toxic species that can drive the spread of tau pathology and neurodegeneration. SIGNIFICANCE STATEMENT Several independent studies have implicated tau protein as central to Alzheimer's disease progression and cell-to-cell pathology propagation. In this study, we investigated the ability of different tau species to propagate pathology in human neurons derived from induced pluripotent stem cells, which to date has not been shown. We demonstrated that tau oligomers, but not monomers, induce accumulation of pathological, hyperphosphorylated tau. This effect was accompanied with neurite degeneration, loss of synapses, aberrant calcium homeostasis, imbalanced neurotransmitter release, and ultimately with neuronal death. This study bridges various tau pathological phenotypes into a single and relevant induced pluripotent stem cell neuronal model of human disease that can be applied to the discovery of the mechanisms of tau-induced neurodegeneration.

[1]  M. Diamond,et al.  Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation* , 2015, The Journal of Biological Chemistry.

[2]  P. Szekeres,et al.  Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates , 2014, The Journal of Biological Chemistry.

[3]  A. Odawara,et al.  Thymoquinone protects cultured hippocampal and human induced pluripotent stem cells-derived neurons against α-synuclein-induced synapse damage , 2014, Neuroscience Letters.

[4]  M. Tolnay,et al.  Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies , 2014, Neuropharmacology.

[5]  J. Isaac,et al.  Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons , 2014, Psychopharmacology.

[6]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[7]  F. Brodsky,et al.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.

[8]  R. Kayed,et al.  Formation and Propagation of Tau Oligomeric Seeds , 2013, Front. Neurol..

[9]  B. Ghetti,et al.  Brain homogenates from human tauopathies induce tau inclusions in mouse brain , 2013, Proceedings of the National Academy of Sciences.

[10]  Pasko Rakic,et al.  A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss , 2013, The Journal of Neuroscience.

[11]  Virginia M. Y. Lee,et al.  Neurofibrillary tangle‐like tau pathology induced by synthetic tau fibrils in primary neurons over‐expressing mutant tau , 2013, FEBS letters.

[12]  Zhong Zhong,et al.  Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. , 2013, Stem cell research.

[13]  Wendy Noble,et al.  Physiological release of endogenous tau is stimulated by neuronal activity , 2013, EMBO reports.

[14]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[15]  M. Diamond,et al.  Cellular mechanisms of protein aggregate propagation. , 2012, Current opinion in neurology.

[16]  M. Citron,et al.  Constitutive secretion of tau protein by an unconventional mechanism , 2012, Neurobiology of Disease.

[17]  C. Zurzolo,et al.  Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* , 2012, The Journal of Biological Chemistry.

[18]  T. Gamblin,et al.  FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions. , 2012, Biochemistry.

[19]  U. Sengupta,et al.  Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau , 2012, Scientific Reports.

[20]  Michael George,et al.  Characterizing Human Ion Channels in Induced Pluripotent Stem Cell–Derived Neurons , 2012, Journal of biomolecular screening.

[21]  E. Mandelkow,et al.  Biochemistry and cell biology of tau protein in neurofibrillary degeneration. , 2012, Cold Spring Harbor perspectives in medicine.

[22]  U. Sengupta,et al.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Jun Wang,et al.  Paired Helical Filaments from Alzheimer Disease Brain Induce Intracellular Accumulation of Tau Protein in Aggresomes* , 2012, The Journal of Biological Chemistry.

[24]  D. Holtzman,et al.  Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.

[25]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[26]  J. Falcón-Pérez,et al.  Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles , 2012, FEBS letters.

[27]  A. McKee,et al.  Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[28]  U. Sengupta,et al.  Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice , 2011, Molecular Neurodegeneration.

[29]  M. Glucksman,et al.  Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[30]  V. Lee,et al.  Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles* , 2011, The Journal of Biological Chemistry.

[31]  I. Bezprozvanny,et al.  The dysregulation of intracellular calcium in Alzheimer disease. , 2010, Cell calcium.

[32]  N. Moerke,et al.  Fluorescence Polarization (FP) Assays for Monitoring Peptide‐Protein or Nucleic Acid‐Protein Binding , 2009, Current protocols in chemical biology.

[33]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[34]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[35]  Ilya Bezprozvanny,et al.  Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease , 2008, Trends in Neurosciences.

[36]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[37]  K. Ashe,et al.  Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy , 2007, The Journal of Neuroscience.

[38]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[39]  V. Lee,et al.  Characterization of two VQIXXK motifs for tau fibrillization in vitro. , 2006, Biochemistry.

[40]  Renato Zenobi,et al.  Immunoassays with direct mass spectrometric detection. , 2006, Analytical chemistry.

[41]  S. Maeda,et al.  Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease , 2006, Neuroscience Research.

[42]  D. Rubinsztein,et al.  Rapamycin alleviates toxicity of different aggregate-prone proteins. , 2006, Human molecular genetics.

[43]  C. Cotman,et al.  A microfluidic culture platform for CNS axonal injury, regeneration and transport , 2005, Nature Methods.

[44]  John Q Trojanowski,et al.  Transgenic animal models of tauopathies. , 2005, Biochimica et biophysica acta.

[45]  R. Nixon.  The calpains in aging and aging-related diseases , 2003, Ageing Research Reviews.

[46]  D. Jameson,et al.  Fluorescence polarization: past, present and future. , 2003, Combinatorial chemistry & high throughput screening.

[47]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[48]  Florence Pasquier,et al.  Tau aggregation in the hippocampal formation: an ageing or a pathological process? , 2002, Experimental Gerontology.

[49]  A. Delacourte,et al.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.

[50]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[51]  P. Davies,et al.  Conformational change as one of the earliest alterations of tau in Alzheimer’s disease , 2000, Neurobiology of Aging.

[52]  D. Jameson,et al.  Quantification of protein-protein interactions using fluorescence polarization. , 1999, Methods.

[53]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[54]  G. Jicha,et al.  Alz‐50 and MC‐1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau , 1997, Journal of neuroscience research.

[55]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[56]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[57]  P. De Camilli,et al.  The distribution of synapsin I and synaptophysin in hippocampal neurons developing in culture , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[58]  M. Kennedy,et al.  Hippocampal Neurons Predisposed to Neurofibrillary Tangle Formation Are Enriched in Type II Calcium/Calmodulin-Dependent Protein Kinase , 1990, Journal of neuropathology and experimental neurology.

[59]  L. Buée,et al.  Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. , 2015, Journal of Alzheimer's disease : JAD.

[60]  W. H. Yu,et al.  Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer’s Disease , 2014, Neurotherapeutics.

[61]  N. Mizushima.  Autophagy in protein and organelle turnover. , 2011, Cold Spring Harbor symposia on quantitative biology.

[62]  R. Zenobi,et al.  Reactivity and applications of new amine reactive cross-linkers for mass spectrometric detection of protein-protein complexes. , 2010, Analytical chemistry.

[63]  J. Ávila,et al.  Characteristics of the binding of thioflavin S to tau paired helical filaments. , 2006, Journal of Alzheimer's disease : JAD.

[64]  H. Levine.  Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.